A Multicenter, Randomized, Evaluator-Blind, No-Treatment Controlled Study of YVOIRE Y-Solution 720: A Volumizing Hyaluronic Acid Filler for Midface Volume Deficit.

Summary

In an evaluator-blind randomized trial in Asian patients, YVOIRE Y-Solution 720 achieved ≥1-grade midface volume improvement in 82% vs 5.1% with no treatment at 26 weeks and maintained 76.2% response at 52 weeks. Adverse reactions were mild and transient, primarily swelling, tenderness, and pain.

Key Findings

• At 26 weeks, ≥1-grade MFVDA-SRS improvement occurred in 82.0% with YYS720 vs 5.1% control (between-group difference 77.0%, 95% CI 66.8–84.0).
• Response durability: 76.2% of YYS720 participants maintained ≥1-grade improvement at 52 weeks.
• Safety profile showed no specific concerns; common local reactions (swelling, tenderness, pain) were mild and transient; GAIS responder rates remained high through 26 weeks.

Clinical Implications

YVOIRE Y-Solution 720 can be offered to suitable patients seeking midface augmentation with expectation of high response rates sustained to 1 year and primarily mild, transient local reactions. Counseling should note evaluator-blind improvements and durability.

Limitations

• No active comparator or participant blinding; control was no-treatment.
• Population limited to Asian participants; generalizability to other populations needs confirmation.

Future Directions

Head-to-head trials versus other volumizing fillers, cost-effectiveness analyses, and studies across diverse populations to confirm generalizability and long-term safety beyond 52 weeks.